Welcome to Amyloidosis: Diagnosis to Treatments!

Amyloidosis is a group of diseases in which abnormal proteins, known as amyloid fibrils, build up in the heart, liver, kidneys, gastro-intestinal tract, lungs, and/or soft tissues. It represents an increasingly recognized but still frequently missed cause of heart failure. Despite increased awareness, diagnosis and management continue to be a challenge. Accurate and timely recognition of this disease has been shown to lead to a better prognosis, increased treatment options, and improved long-term survival. This virtual conference focused on Amyloidosis offers clinicians a comprehensive and multidisciplinary approach to effectively recognize, workup, and treat amyloid disease.

Sponsored By:

custom image

Accreditation Statement
This meeting is provided by the American Association of Heart Failure Nurses (AAHFN). The American Association of Heart Failure Nurses (AAHFN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's (ANCC) Commission on Accreditation.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Contact Hours
Attendees may earn (up to) *3.00 contact hours by attending the meeting and completing the evaluation.

How to Get Your Certificate 
Attendees can earn one nursing contact hour for every hour of educational time. Learners must complete an evaluation to receive contact hours. Evaluation forms should be submitted after the meeting.

1.) Once the session has ended visit the Evaluations tab on the event page HERE
**Please note you must be logged in to view this tab.
2.) Click Take Evaluation button under the session
3.) Answer the questions and click Submit
4.) Once the evaluation is submitted the Take Evaluation button will change to Print Certificate
5.) Click Print Certificate to save or print for their records

Disclosure/Conflicts of Interest

The planners and faculty for this activity do not have any relevant relationships to disclose, unless listed below. Any resulting conflicts of interest have been resolved according to ANCC guidance:

Dr. Farooq Sheikh disclosed:
1.) Alnylam: I received royalties for advisory board, educational development.
2.) Akcea: I received royalties for advisory board, educational development.
3.) Pfizer: I received royalty for serving on an advisory board

Disclosure of Commercial Support
AAHFN received commercial support from the following organization: Pfizer, Inc.